Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Immunology/Inflammation >> Complement System

Complement System

The complement system helps or “complements” the ability of antibodies and phagocytic cells to clear pathogens from an organism. It is part of the immune system called the innate immune system that is not adaptable and does not change over the course of an individual's lifetime. The complement system consists of a number of small proteins found in the blood, in general synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end-result of this activation cascade is massive amplification of the response and activation of the cell-killing membrane attack complex. Over 30 proteins and protein fragments make up the complement system. Three biochemical pathways activate the complement system: the classical complement pathway, the alternative complement pathway, and the lectin pathway.

Targets for  Complement System

Products for  Complement System

  1. Cat.No. Product Name Information
  2. GC38880 (Z)-Leukadherin-1 (Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses. (Z)-Leukadherin-1 Chemical Structure
  3. GC60040 ADH-503 ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses. ADH-503 Chemical Structure
  4. GC69582 ARC186

    ARC 186 is a nucleic acid adapter that serves as an efficient complement inhibitor by blocking the activation of C5 catalyzed by convertase.

     ARC186 Chemical Structure
  5. GC35481 BCX 1470 BCX 1470 inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin. BCX 1470 Chemical Structure
  6. GC35482 BCX 1470 methanesulfonate BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin. BCX 1470 methanesulfonate Chemical Structure
  7. GC35575 C3a (70-77) TFA C3a (70-77) TFA Chemical Structure
  8. GC31928 C3a 70-77 (Complement 3a (70-77)) C3a 70-77 (Complement 3a (70-77)) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a. C3a 70-77 (Complement 3a (70-77)) Chemical Structure
  9. GC66410 Cemdisiran Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the treatment of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein. Cemdisiran Chemical Structure
  10. GC35724 Complement C5-IN-1 Complement C5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (C5). Complement C5-IN-1 Chemical Structure
  11. GC62901 Complement factor D-IN-2 Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 Chemical Structure
  12. GC15251 Compstatin Complement inhibitor Compstatin Chemical Structure
  13. GC17510 Compstatin control peptide control peptide for Compstatin, a complement inhibitor Compstatin control peptide Chemical Structure
  14. GC61469 Compstatin TFA Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA Chemical Structure
  15. GC67721 CP-447697 CP-447697 Chemical Structure
  16. GC38162 Danicopan Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan Chemical Structure
  17. GC40775 Dexamethasone

    Dexamethasone, as one member of the glucocorticoid family, can protect against arthritis-related changes in cartilage structure and function, including matrix loss, inflammation and cartilage viability.

     Dexamethasone Chemical Structure
  18. GC64796 Eculizumab

    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5.

     Eculizumab Chemical Structure
  19. GC60149 EG01377 dihydrochloride EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects. EG01377 dihydrochloride Chemical Structure
  20. GC64892 Factor B-IN-1 Factor B-IN-1 is a Factor B inhibitor extracted from patent WO2013164802A1, Example 24. Factor B-IN-1 Chemical Structure
  21. GC64878 Factor D inhibitor 6 Factor D inhibitor 6 is a potent, highly selective and orally active factor D (FD) inhibitor with an IC50 of 30 nM and a Kd of 6 nM. Factor D inhibitor 6 Chemical Structure
  22. GC36035 FD-IN-1 FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. FD-IN-1 Chemical Structure
  23. GC62479 Iptacopan hydrochloride LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. Iptacopan hydrochloride Chemical Structure
  24. GC68029 JPE-1375 JPE-1375 Chemical Structure
  25. GC62273 JR14a JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a Chemical Structure
  26. GC17263 Leukadherin 1 CD11b/CD18 activator Leukadherin 1 Chemical Structure
  27. GC36472 LNP023 LNP023 (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 value of 10 nM. LNP023 Chemical Structure
  28. GC66874 N-((Allyloxy)carbonyl)-N-methyl-L-alanine N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. N-((Allyloxy)carbonyl)-N-methyl-L-alanine can be used for the synthesis of inhibitors of complement factor D. Complement factor D inhibitors can be used in the research of immune system related disease. N-((Allyloxy)carbonyl)-N-methyl-L-alanine Chemical Structure
  29. GC12342 NDT 9513727 C5a receptor (C5aR) competitive antagonist NDT 9513727 Chemical Structure
  30. GC69592 NRP1 antagonist 1

    NRP1 antagonist 1 (compound 12a) is an effective NRP1 inhibitor with an IC50 of 19.1 μM. It has potential for use in cancer research.

     NRP1 antagonist 1 Chemical Structure
  31. GC69684 Pelecopan

    Pelecopan (BCX9930) is an effective and selective complement factor D inhibitor with oral activity. Its IC50 value is 14.3 nM. Pelecopan can target complement factor D to prevent intravascular and extravascular hemolysis in PNH, as well as other diseases mediated by alternative pathways.

     Pelecopan Chemical Structure
  32. GC10449 PMX 205 C5a receptor peptide antagonist PMX 205 Chemical Structure
  33. GC34434 PMX 205 Trifluoroacetate PMX 205 Trifluoroacetate is a potent complement C5a receptor (C5aR; CD88) antagonist. PMX 205 Trifluoroacetate Chemical Structure
  34. GC50176 PMX 53 Potent C5a receptor antagonist PMX 53 Chemical Structure
  35. GC50238 PMX 53c Negative control for PMX 53 PMX 53c Chemical Structure
  36. GC63151 POT-4 POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 Chemical Structure
  37. GC69803 Ravulizumab

    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds specifically and with high affinity to human complement protein C5. Ravulizumab can be used in the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

     Ravulizumab Chemical Structure
  38. GC11800 SB 290157 (trifluoroacetate salt) SB 290157 (trifluoroacetate salt) is a potent and selective C3a receptor antagonist with an IC50 of 200 nM. SB 290157 (trifluoroacetate salt) Chemical Structure
  39. GC66348 Sutimlimab Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. Sutimlimab Chemical Structure
  40. GC70017 Tesidolumab

    Tesidolumab (LFG316) is a fully human IgG1/Λ monoclonal antibody against C5, with a molecular weight of 143 kDa (excluding glycosylation). Tesidolumab (LFG316) blocks the cleavage of C5, preventing the subsequent formation of membrane attack complex.

     Tesidolumab Chemical Structure
  41. GC61335 TLQP-21 TFA TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA Chemical Structure
  42. GC63858 Vemircopan Vemircopan (ALXN2050) is an orally active complement factor D inhibitor. Vemircopan Chemical Structure
  43. GC70116 Vesencumab

    Vesencumab (MNRP-1685A) is an IG1 antibody targeting neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and blocks its coupling with VEGFR-2. Vesencumab has antiangiogenic and antitumor activity. Vesencumab can be used for research on metastatic solid tumors, including ovarian cancer.

     Vesencumab Chemical Structure
  44. GC17129 W 54011 C5a receptor antagonist W 54011 Chemical Structure
  45. GC70170 Zilucoplan

    Zilucoplan (RA101495) is a 15-amino acid cyclic peptide and an effective inhibitor of complement component 5 (C5). Zilucoplan can be used in research on immune-mediated necrotizing myopathy (IMNM).

     Zilucoplan Chemical Structure

44 Item(s)

per page

Set Descending Direction